Compounds > d13-9001
Page last updated: 2024-11-12

d13-9001

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

D13-9001: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID17757337
CHEMBL ID394052
MeSH IDM0517455

Synonyms (8)

Synonym
CHEMBL394052
[{2-[({[(3r)-1-{8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-4-oxo-3-[(e)-2-(1h-tetrazol-5-yl)ethenyl]-4h-pyrido[1,2-a]pyrimidin-2-yl}piperidin-3-yl]oxy}carbonyl)amino]ethyl}(dimethyl)ammonio]acetate
d13-9001
Q27464316
CS-0087804
HY-124819
2-[2-[[(3r)-1-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-4-oxo-3-[(e)-2-(2h-tetrazol-5-yl)ethenyl]pyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl]oxycarbonylamino]ethyl-dimethylazaniumyl]acetate
AKOS040732911
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID309785Half life in Sprague-Dawley rat at 20 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309775Mean residential time (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309774Mean residential time (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309772AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309778Clearance (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309796Half life in cynomolgus monkey at 1 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309764Aqueous solubility at pH 6.82007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309787Drug level in cynomolgus monkey serum at 5 mg/kg, iv after 1 hr2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309769Drug level in Sprague-Dawley rat serum at 5 mg/kg, iv after 2 hrs2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309788AUC (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309773AUC (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309771AUC (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309770Drug level in Sprague-Dawley rat serum at 20 mg/kg, iv after 2 hrs2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309766Toxicity in mouse assessed as lethal effect at 100 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309792Clearance (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309780Volume of distribution at steady state (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309791Mean residential time (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309789AUC (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309768Drug level in Sprague-Dawley rat serum at 1.25 mg/kg, iv after 2 hrs2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309781Volume of distribution at steady state (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309784Half life in Sprague-Dawley rat at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309786Drug level in cynomolgus monkey serum at 1 mg/kg, iv after 1 hr2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309790Mean residential time (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309793Clearance (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309762Inhibition of Pseudomonas aeruginosa PAM1723 MexAB-OprM assessed as drug level required to decrease MIC of levofloxacin in presence of 0.125% HAS2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309761Inhibition of Pseudomonas aeruginosa PAM1723 MexAB-OprM assessed as drug level required to decrease MIC of levofloxacin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309763Inhibition of Pseudomonas aeruginosa PAM1723 MexAB-OprM assessed as drug level required to decrease MIC of aztreonam2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309776Mean residential time (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309797Half life in cynomolgus monkey at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309794Volume of distribution at steady state (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309777Clearance (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309795Volume of distribution at steady state (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309779Clearance (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309782Volume of distribution at steady state (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309783Half life in Sprague-Dawley rat at 1.25 mg/kg, iv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		2.2110carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.2110beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		2.2110penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
beta-lactams
2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.		2.2110beta-lactam antibiotic allergen;
beta-lactam
phenylalanine arginine beta-naphthylamide
phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source		2.0510peptide
aztreonam
[no description available]		2.0310beta-lactam antibiotic allergen;
monobactam		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
piperidines
Piperidines: A family of hexahydropyridines.		3.250
ConditionIndicatedRelationship StrengthStudiesTrials
Adverse Drug Event
[description not available]		02.0310
Infections, Pseudomonas
[description not available]		02.0310
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.0310
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		02.0310